{"title":"Potassium-Competitive Acid Blockers for the Treatment of Gastroesophageal Reflux Disease","authors":"J. Kothadia, C. Howden","doi":"10.1177/26345161231181357","DOIUrl":null,"url":null,"abstract":"Current treatments for gastroesophageal reflux disease (GERD) and other acid-related disorders either block stimulation of the parietal cell (H2-receptor antagonists) or inhibit gastric H+/K+-ATPase (proton pump inhibitors; PPIs). PPIs are usually very effective in healing esophageal erosions and improving heartburn in patients with GERD. However, the PPIs have a slow onset of action and do not provide complete symptom resolution in all patients. Therefore, there is a need for agents that offer a fast onset of action and sustained acid suppression to maximize both mucosal healing and symptom control. Potassium-competitive acid blockers (P-CABs) are a relatively novel class of acid suppressants showing potential for the management of GERD and other acid-related disorders. This article focuses on the likely role of P-CABs for treating GERD.","PeriodicalId":73049,"journal":{"name":"Foregut (Thousand Oaks, Calif.)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Foregut (Thousand Oaks, Calif.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/26345161231181357","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Current treatments for gastroesophageal reflux disease (GERD) and other acid-related disorders either block stimulation of the parietal cell (H2-receptor antagonists) or inhibit gastric H+/K+-ATPase (proton pump inhibitors; PPIs). PPIs are usually very effective in healing esophageal erosions and improving heartburn in patients with GERD. However, the PPIs have a slow onset of action and do not provide complete symptom resolution in all patients. Therefore, there is a need for agents that offer a fast onset of action and sustained acid suppression to maximize both mucosal healing and symptom control. Potassium-competitive acid blockers (P-CABs) are a relatively novel class of acid suppressants showing potential for the management of GERD and other acid-related disorders. This article focuses on the likely role of P-CABs for treating GERD.